Hansa Biopharma: Adding growth capital ahead of the US launch - Redeye

Hansa has done a directed share issue adding SEK 420m in growth capital mainly supporting the US launch of Idifirix and to progress with an already extensive pipeline of opportunities ahead. A sizeable directed share issue directed to international institutions at a minimal rebate can be considered as a sign of strength in these market conditions.

Länk till analysen i sin helhet: https://www.redeye.se/research/868517/hansa-biopharma-adding-growth-capital-ahead-of-the-us-launch?utm_source=finwire&utm_medium=RSS